INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancies (Ryan et al., 2014) . A hallmark of PDA is a pronounced fibroinflammatory stroma, which contributes to disease initiation and progression (Stromnes et al., 2014; Vonderheide and Bayne, 2013) . The inflammatory infiltrates that populate PDA lesions are predominantly immunosuppressive in nature and include tumor-associated macrophages, myeloid-derived suppressor cells (MDSCs), gd T cells, and regulatory T (Treg) cells (Daley et al., 2016; Hiraoka et al., 2006; Markowitz et al., 2015) . Murine models of oncogenic Ras-driven PDA recapitulate many of these immune signatures (Bayne et al., 2012; Clark et al., 2007; Daley et al., 2016) . Understanding the mechanisms underlying the immunosuppressive effects of these cell types is therefore essential to develop effective immunotherapies for the treatment of PDA. CD4 + Foxp3 + Treg cells are crucial for the maintenance of immunological self-tolerance and have the ability to actively impede the anti-tumor immune response in a variety of cancer types (Josefowicz et al., 2012) . In PDA, the accumulation of Treg cells in the tumor microenvironment occurs during the preinvasive stage of the disease (Clark et al., 2007; Hiraoka et al., 2006) . A high frequency of Treg cells in the pre-neoplastic pancreas is associated with poor prognosis and reduced survival in murine and human PDA (Hiraoka et al., 2006; Tang et al., 2014) . Accordingly, Treg cell depletion in combination with conventional PDA treatment strategies has been shown to enhance cancer-specific T cell activation in preclinical studies (Keenan et al., 2014; Leao et al., 2008) . A variety of mechanisms for Treg cell-mediated suppression of effector T cell responses have been proposed, including direct elimination of effector T cells and competition with effector T cells for access to antigen-presenting dendritic cells (DCs) (Josefowicz et al., 2012; Kim et al., 2007; Nishikawa and Sakaguchi, 2010) . Treg cells have also been shown to suppress DC immunogenicity in in vitro co-culture systems (Cederbom et al., 2000; Onishi et al., 2008) . However, the precise mechanism of Treg cell-dependent immune modulation in PDA remains poorly understood.
Here, we demonstrate that Treg cells promote PDA development through the suppression of CD8 + T cell-dependent antitumor immunity. Intratumoral Treg cells engage in prolonged interactions with tumor-associated CD11c + DCs and reduce their expression of molecules important for T cell activation. Treg cell ablation leads to the restoration of immunogenic tumor-associated CD11c + DCs and increases in CD8 + T cell activation. Importantly, Treg cell ablation results in an inhibition in tumor growth that is dependent on interferon-g (IFN-g) expressed by CD8 + T cells. Thus, the targeting of Treg cells in PDA may facilitate anti-tumor immunity by harnessing the immune-stimulatory potential of tumor-associated DCs.
RESULTS

Treg Cells Are Required for Pancreatic Tumorigenesis
To discern the functional role of Treg cells in the development of pancreatic neoplasia, we employed an orthotopic implantation model in which primary Kras G12D -expressing pancreatic ductal epithelial cells (Kras
G12D
-PDECs) labeled with GFP (GFP-Kras
-PDECs) are injected into the pancreata of syngeneic C57BL/6 wild-type (WT) mice (Pylayeva-Gupta et al., 2013) . This model histologically recapitulates the pre-invasive stages of pancreatic intraepithelial neoplasia (PanIN) development and induces an intra-pancreatic immune response similar to that observed in the genetically engineered p48-Cre;Kras G12D (KC) mouse model of pancreatic neoplasia (Clark et al., 2007; Pylayeva-Gupta et al., 2012) . Furthermore, it preserves the natural histopathological features of disease development in that the lesions are produced in a focal manner and evolve in the context of normal pancreatic tissue. The implanted cells form a discernable mass (hereafter referred to as the tumor) that can be isolated along with the immediately adjacent parenchyma (hereafter referred to as the tumor microenvironment [TME]) and analyzed by flow cytometry and immunohistochemistry. We first assessed the frequency of tumor-associated Treg cells using the lineage specification transcription factor of Treg cells, forkhead box P3 (Foxp3) (Hori et al., 2003) . Treg cells were readily detected within 1 week post-implantation of GFP-Kras G12D -PDEC tumors and increased another $2.5-fold by 5 weeks ( Figures 1A and 1B) , whereas Treg cells were rare in sham-injected or WT pancreata (data not shown). Importantly, Foxp3 + Treg cells in the TME displayed elevated levels of the activation markers CD44 (Figure 1C) , a hyaluronic acid receptor expressed on activated and memory Treg cell populations (Darrasse-Jè ze et al., 2009); cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a Treg cell effector molecule (Wing et al., 2008) ; and programmed death 1 (PD-1), a negative costimulatory molecule (Keir et al., 2008 ), compared to tumor-draining pancreatic lymph nodes (Pan LNs) ( Figures 1D and S1A ). These data indicate that the development of pancreatic neoplasia is accompanied by the progressive accumulation of activated Treg cells.
Next, we examined the effect of Treg cell depletion on pancreatic neoplasia by implanting GFP-Kras G12D -PDECs into the pancreata of Foxp3 DTR mice in which the human diphtheria toxin (DT) receptor (DTR) is expressed under the control of the Foxp3 locus (Kim et al., 2007) (Figure 1E ). DT treatment 1 week following orthotopic implantation resulted in >90% ablation of Treg cells within the pancreatic TME ( Figure 1F ) and a significant reduction in tumor growth (Figures 1G and 1H) . DT treatment had no effect on the growth of GFP-Kras
-PDECs implanted into WT mice ( Figure S1B ). The anti-tumor effect of Treg cell ablation persisted for 5 weeks post-implantation ( Figure S1C ). In addition, using an anti-CD25 neutralizing antibody to deplete Treg cells in KC mice, we observed a significant delay in disease progression ( Figures S2A-S2C) . Furthermore, Treg cell depletion in mice implanted with KPC cells derived from pancreata of a Kras G12D/+ ;Trp53 R172H/+ ;Pdx1-Cre (KPC) mouse (Byrne and Vonderheide, 2016; Lo et al., 2015) was accompanied by a marked reduction in tumor volume and prolonged overall survival (Figures 1I and 1J) . Together, these data demonstrate that Treg cells contribute to pancreatic tumor growth at both the early and late stages of disease progression.
Anti-tumor Immunity of Treg Cell Ablation Is Dependent on IFN-g-Producing CD8 + T Cells
Since anti-tumor responses require functional effector CD4 + and CD8 + T cells, we assessed the effect of Treg cell ablation on effector T cells in the TME, tumor-draining pancreatic lymph nodes (Pan LNs) and peripheral inguinal lymph nodes (iLNs). DT-induced Treg cell ablation resulted in the expansion and activation of tumor infiltrating CD4 + and CD8 + T cells at all sites . However, we have observed that intratumoral Treg cells express higher levels of effector molecules CTLA-4 and PD-1 (the latter being regulated by antigen exposure) relative to Treg cells in the tumor-draining Pan LNs and iLNs ( Figures 1D and S1A ). Thus, while we cannot formally exclude a contribution of effector CD8 + T cells that have originated from tumor-draining Pan LNs to the anti-tumoral effect of DT-induced Treg cell depletion, the properties of the TMEassociated Treg cells suggest a primary role for tumor-resident Treg cells in mediating immunosuppression.
We then sought to determine whether the anti-tumor effect of Treg cell ablation is mediated through CD4 + or cytotoxic CD8 + T cell activation. To this end, Treg cells were ablated alone or in combination with either CD4 + or CD8 + T cell depletion using CD4-or CD8-depleting antibody, and tumor growth was measured after 15 days. The depletion of CD4 + T cells resulted in reduction of tumor growth similar to that observed in Treg cell ablation. However, the simultaneous depletion of CD4 + T cells in combination with Treg cell ablation did not further decrease tumor growth compared to Treg cell depletion alone ( Figure S3E ), indicating that CD4 + Foxp3 À T cells are dispensable for the anti-tumor effect of Treg cell ablation. In contrast, the anti-tumor response observed in the setting of Treg cell ablation was reversed when combined with CD8 + T cell depletion ( Figure 2E ). Since only CD8 + T cells displayed a significant increase in the production of IFN-g, a potent tumoricidal cytokine (Shankaran et al., 2001) , we further investigated the role of IFN-g in mediating the immune response to pancreatic neoplasia in orthotopic implant-bearing WT or Foxp3 DTR mice treated with a neutralizing anti-IFN-g monoclonal antibody (mAb). While IFN-g blockade in WT mice did not affect tumor growth, the concurrent administration of anti-IFN-g antibody and DT to Foxp3 DTR mice abolished the inhibitory effect of Treg cell ablation on tumor growth ( Figure 2F ). Histological analysis revealed that the combined depletion of Treg cells and IFN-g blockade was associated with the expansion of neoplastic lesions and a reduction in the frequency of apoptotic cells ( Figures 2G-2I the immune response Schildknecht et al., 2010; Tang et al., 2006) . To test whether such interactions might be relevant to the immunosuppressive function of Treg cells in the context of pancreatic neoplasia, we employed intravital two-photon laser-scanning microscopy (TPLSM). We first assessed the prevalence within the TME of cells expressing CD11c, an integrin that is enriched in DCs, by implanting GFPKras
-PDECs into the pancreata of CD11c-EYFP mice. CD11c + cells were rare in the normal pancreas but abundantly present within the neoplastic lesions formed by the orthotopically implanted GFP-Kras We next sought to characterize the nature of the CD11c-yellow fluorescent protein (YFP) cells recruited to tumors formed by the implanted GFP-Kras G12D -PDECs. In agreement with a previous study reporting that, in CD11c-EYFP mice, the cells visualized by in vivo TPLSM are DCs (Lindquist et al., 2004) , the CD11c-YFP cells expressed the DC markers CD11c, major histocompatibility complex (MHC) class II, and CD135 (Flt3) ( Figure 4A ). Expression of the macrophage marker F4/80 was detected only in a small subset ($8%) of the CD11c-YFP cells ( Figure 4B) . Notably, the CD11c-YFP cells located in the tumor-proximal region (within 50 mm of the tumor margin) exhibited lower motility and shorter displacement trajectory compared to CD11c-YFP cells located distally to the tumor (more than 50 mm from the tumor border) (Figures 4C-4E) . Furthermore, the CD11c-YFP cells that were closely juxtaposed to the tumor had a dendritic morphology ( Figure 3A) .
In Figure 4H ).
Tumor-Associated CD11c + DCs Display a Tolerogenic Phenotype
The function of DCs depends on their maturation and activation status, which is defined by the expression of costimulatory molecules on their cell surface (Steinman et al., 2003) . Expression levels of the maturation marker MHC class II (I-A d ) and the costimulatory molecules CD40 and CD86 (B7.2) on tumor-associated CD11c + DCs decreased over time in the pancreatic TME ( Figure 5A ). Similarly, in KC mice, expression of the maturation markers on CD11c + DCs was significantly lower in the pancreas than in the Pan LNs ( Figure S6A ) and in WT mice ( Figure S6B ). These observations indicate that tumor-associated DCs are immature or semi-mature DCs and as such are likely to drive a tolerogenic response during tumor progression. Consistent with this postulate, we found that tumor-associated DCs express indoleamine 2,3-dioxygenase (IDO), an enzyme implicated in the suppression of T cell responses and the promotion of immune tolerance (Munn and Mellor, 2016 ) ( Figure 5B ). Expression of IDO in DCs was also observed in human PDA, underscoring the potential pathophysiological relevance of this observation ( Figure 5C ).
The Tolerogenic Phenotype of Tumor-Associated CD11c + DCs Is Dependent on Treg Cells
Treg cells are endowed with the capacity to regulate costimulatory molecules on DCs through cell-contact-dependent mechanisms in vitro (Cederbom et al., 2000; Onishi et al., 2008; Qureshi et al., 2011) . Given our observations that Treg cells engage in stable interactions with tumor-associated DCs, we investigated whether Treg cells may downregulate costimulatory molecules expressed on DCs. Implantation of GFP-Kras
G12D
-PDECs into the pancreata of Foxp3 DTR mice followed by DT treatment was accompanied by a significant increase in the frequency of tumor-associated CD11c + DCs ( Figures 6A and 6B) . Furthermore, the expression levels of costimulatory molecules on tumor-associated CD11c + MHC class II + DCs were significantly increased in the absence of Foxp3 + Treg cells ( Figures 6C and S6C ). In 
DISCUSSION
Tumor-associated inflammation is a dynamic process involving the infiltration of multiple subtypes of leukocytes into the tumor stroma. A prominent component of the immune infiltrate is Treg cells, the presence of which correlates with poor clinical outcome in a variety of cancer types (Shang et al., 2015; Tang et al., 2014) . In oncogenic Kras
G12D
-induced pancreatic neoplasia, immune cell infiltration is an early and consistent event (Clark et al., 2007; Guerra et al., 2007) . However, the exact role of Treg cells in pancreatic tumorigenesis is poorly understood. Here, we demonstrate that in the context of pancreatic neoplasia, intratumoral Treg cells play a tumor-promoting role by conferring immunosuppressive properties to tumor-associated CD11c + DCs. This limits the activation of tumor-infiltrating CD8 + T cells, resulting in the reduction of IFN-g production and a defect in tumor rejection.
The mechanisms by which Treg cells are recruited into the TME are not well understood. We have found that Treg cells accumulate around GFP-Kras
-PDEC grafts within 1 week post-implantation. The short duration of this interval suggests that the neoplastic cells themselves may play a direct role in promoting Treg cell infiltration. Indeed, Kras
-PDECs (unpublished data) and pancreatic cancer cells can produce high levels of the Treg cell attractants CXCL10, CCL5, and vascular endothelial growth factor (VEGF) that trigger the migration of Treg cells through interaction with the Treg cell-surface receptors CXCR3 (Lunardi et al., 2015) , CCR5 (Tan et al., 2009) , and neuropilin-1 (Hansen et al., 2012) , respectively. Other cells within the TME, such as pancreatic stellate cells and tumorinfiltrating MDSCs, have also been reported to express high levels of Treg cell chemotactic factors, including CXCL10, CCL3, CCL4, and CCL5 (Lunardi et al., 2015; Schlecker et al., 2012) . Thus, the intratumoral accumulation of all of the above cell types over the course of pancreatic tumor development may augment Treg cell infiltration and contribute to their expansion.
Our data demonstrate that the Treg cells that are recruited to the tumor graft are initially neuropilin-1 hi (data not shown) and CD44 low and are therefore most likely naive Treg cells of thymic origin that are selected on self-antigens (Weiss et al., 2012) . At later stages, the vast majority of the intratumoral Treg cells exhibit a CD44 high memory/effector phenotype. It is not clear whether this shift reflects an in situ activation event or the recruitment of memory/effector Treg cells. The possibility that the activated phenotype is acquired in situ is supported by our observation that Treg cells engage in prolonged interactions with DCs within the TME. The DC-Treg cell interaction has been shown to potentiate Treg cell activation through either antigen recognition or the interaction of semaphorin 4A expressed on DCs with the Treg cell-expressed receptor neuropilin-1 (Delgoffe et al., 2013; Sarris et al., 2008) . Of note, we have determined that neuropilin-1 is abundantly expressed in intratumoral Treg cells at all stages of pancreatic tumor progression (data not shown). Thus, the recruitment of CD44 low naive Treg cells that have low expression of CXCR3 and CCR5 could potentially be mediated through the chemotactic interaction between neuropilin-1 and tumorderived VEGF.
Experimental depletion of Treg cells by administration of anti-CD25 antibodies or by DT administration to Foxp3
DTR mice has been shown to inhibit the growth of a variety of tumors, consistent with a role for Treg cells in suppressing anti-tumor immune responses (Bos et al., 2013; Joshi et al., 2015; Teng et al., 2010) . However, the effector mechanisms by which Treg cells modulate anti-tumor immunity appear to vary between different tumor types. For example, in breast cancer, the anti-tumoral effect of Treg cell ablation is dependent on CD4 + T cells and IFN-g, pointing to a potential role for CD4 + T cells as a non-redundant source of protective IFN-g (Bos et al., 2013) . In fibrosarcomas, the various conventional helper T cells, is to promote the onset of pancreatic neoplasia by modulating the activity of cytotoxic CD8 + T cells. Ultimately, in human tumors, the potential therapeutic benefits of Treg cell targeting might be influenced by tumor-type specific mechanisms of immune tolerance. Our findings identify DCs as critical targets of Treg cells to suppress anti-tumor immunity. DCs are essential determinants of the tumor immune response through the induction of immunogenicity or tolerance (Steinman et al., 2003) . Tolerogenic DCs play a crucial role in immune tolerance through the inhibition of T cell proliferation or the induction of T cell anergy or Treg cell generation, resulting in diminished T cell-dependent anti-tumor immunity (Maldonado and von Andrian, 2010; Steinman et al., 2003) . Tumor-associated DCs have been shown to display tolerogenic properties such as low expression of costimulatory molecules, low ability to process and present antigen to tumor-specific T cells, and low production of proinflammatory cytokines in a variety of cancer types (Bauer et al., 2014; Kim et al., 2007; Pinzon-Charry et al., 2005) . The accumulation of tolerogenic tumorassociated DCs has been attributed to tumor-and TME-derived immunosuppressive factors such as VEGF, interleukin-10 (IL-10), transforming growth factor b (TGF-b), and PGE2 that modulate DC maturation and favor tolerogenic DC differentiation (Ghiringhelli In addition, it has been proposed that Treg cell-mediated DC suppression could be mediated by direct cell-to-cell contact, leading to the downregulation of costimulatory molecules and apoptosis in DCs (Bauer et al., 2014; Boissonnas et al., 2010; Larmonier et al., 2007) . Consistent with this idea, we have found that DCs interact with Treg cells in the pancreatic TME. The interaction between DCs and Treg cells has also been reported in breast cancer (Bauer et al., 2014) , TA-TLSs in lung cancer (Joshi et al., 2015) , and tumor-draining LNs (Boissonnas et al., 2010) , suggesting that a contact-based crosstalk between these cell populations may be a general feature of tumor immune evasion.
The tolerogenic nature of DCs that are recruited to the pancreatic TME is also indicated by their expression of IDO. IDO-expressing DCs found at the tumor site and in tumor-draining LNs have been implicated in suppressing anti-tumor T cell responses to tumor-derived antigens and in promoting immune tolerance (Munn et al., 2002; Sharma et al., 2007) . Mechanistically, the tolerogenic effect of IDO expression has been attributed to its enzymatic activity that leads to a reduction of tryptophan levels and the accumulation of metabolites of tryptophan catabolism, resulting in the inhibition of T cell proliferation and effector T cell toxicity (Munn and Mellor, 2016) . A principal mechanism by which the expression of IDO in DCs can be upregulated is through the interaction of costimulatory molecules CD80 and CD86 with CTLA-4 expressed on Treg cells (Fallarino et al., 2003) . The potential relevance of this mechanism to IDO expression in tumorassociated DCs is indicated by our observation that tumor-associated Treg cells display elevated levels of CTLA-4 compared to other lymphoid tissues. Intriguingly, IDO has been shown to modulate the immunosuppressive phenotype of Treg cells by controlling the levels of Akt signaling (Sharma et al., 2015) , suggesting that the Treg cell-DC interaction in the TME may be involved in bidirectional communication. Thus, the establishment of immune tolerance in the pancreatic TME may in part be driven by a feed-forward mechanism involving the reciprocal interaction between DCs and Treg cells that mutually reinforces their immunosuppressive activities. Further insights from studies employing autochthonous mouse models of PDA as well as human PDA samples will be required to fully assess whether signal pathways that are downregulated in tumor-associated DCs through interactions with Treg cells can be therapeutically exploited to improve the anti-tumor immune response. In summary, our study provides insights into Treg cell function in PDA progression. We demonstrate that Treg cells confer an immunosuppressive phenotype on tumor-associated CD11c Data are presented as mean ± SEM. *p < 0.05. See also Figure S6 . Orthotopic Tumor Model Isolation, culture, and adenoviral infection of PDECs was carried out as previously described (Pylayeva-Gupta et al., 2013) . KPC cells isolated from KPC mice were a gift from Dr. R.H. Vonderheide (Byrne and Vonderheide, 2016; Lo et al., 2015) . Orthotopic implantation is described in Supplemental Experiment Procedures. Tumor volume was calculated using the formula pLW 2 /6. T cells by flow cytometry (E) (n = 5-7 mice). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. NS, not significant. See also Figure S7 .
In Vivo Treatments
For Treg cell ablation studies, DT (Sigma-Aldrich) was injected intraperitoneally (i.p.) at 50 mg per kg of body weight at the indicated times. For neutralization and depletion studies, anti-mouse IFN-g (1 mg, clone XMG1.2, Bio X Cell), anti-mouse CD11c (500 mg, clone N418, Bio X Cell), anti-mouse CD8 (250 mg, clone 53-6.72, Bio X Cell), anti-mouse CD4 (150 mg, clone GK1.5, Bio X Cell), or anti-mouse CD25 (500 mg, clone PC-61.5.3, Bio X Cell) was injected i.p. at the indicated times. Isotype control antibodies used were rat IgG1, Armenian hamster IgG, or rat IgG2a from Bio X Cell, respectively.
Intravital TPLSM of Pancreas Pancreata were prepared microsurgically for intravital microscopy. Mice were anaesthetized by an initial intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine and boosted with a half dose every 30-60 min. The spleen and pancreatic tail were externalized through a 1-cm left abdominal side incision, gently pulled out, and carefully fixed with a custom-made plastic apparatus, without inducing vascular damage. The mouse was then placed on the stage mounted with a coverslip so that the pancreas was in contact with the coverslip for imaging with an inverted objective. Detailed image acquisition and analysis are described in Supplemental Experimental Procedures.
Immunofluorescence
Mouse pancreata were harvested and fixed with 4% PFA for 1 hr at 4 C and cryoprotected with 30% sucrose for 18 hr. Fixed samples were then embedded in optimum cutting temperature (OCT) compound and snap frozen at À80 C until further processing.
The use of human tissue was reviewed and approved by the Institutional Review Board at the NYU School of Medicine and samples (provided by the Tissue Acquisition and Biorepository Service) were obtained with informed consent. 5-mm-thick sections from formalin-fixed paraffin-embedded samples were used for immunofluorescence staining. Detailed immunofluorescence, immunochemistry, H&E staining, and antibody information can be found in Supplemental Experimental Procedures.
Flow Cytometry
For mononuclear cell isolation, pancreata were minced into small fragments and incubated in collagenase V (1 mg/mL, Sigma) with DNase I (Roche) in RPMI-1640 at 37 C for 30 min with 150 rpm agitation. Dissociated cells were passed through a 70-mm cell strainer and washed with RPMI-1640 supplemented with 10% fetal calf serum (FCS). Total mononuclear cells were further purified by 47% Percoll (GE Healthcare) gradient centrifugation. Spleens and LNs were mechanically homogenized and passed through a 70-mm cell strainer. Red blood cells were lysed using ACK Lysis buffer (Lonza). Isolated cells were incubated with anti-CD16/CD32 antibody (BD PharMingen) to prevent non-specific antibody binding. Surface antigens were stained with the antibodies described in Supplemental Experimental Procedures. The corresponding isotype IgGs were stained. Dead cells were excluded using LIVE/DEAD Fixable Aqua Dead Cell Stain (Invitrogen). Multiparameter analysis was performed on a LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star). The geometric mean fluorescence intensity (MFI) was calculated as follows: MFI = MHC class II, CD40, CD80, or CD86 geometric mean À isotype geometric mean. Detailed Foxp3 and intracellular cytokine staining for flow cytometry and antibody information is described in Supplemental Experimental Procedures.
Statistical Analysis
All data are presented as mean ± SEM. Unpaired Student's t tests or nonparametric Mann-Whitney U tests were used to compare two variables as indicated in the figure legends. One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test was used for multiplegroup comparison. Kaplan-Meier survival curves were calculated using the survival time of each mouse. The log-rank test was used to test for significant differences between two groups. Statistical analyses were performed with GraphPad Prism (GraphPad) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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